title: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.
abstract: BACKGROUND
  Allergic rhinitis represents a global health problem affecting 10% to 20% of the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat the approximately 500 million affected patients globally.
  
  
  OBJECTIVE
  To develop explicit, unambiguous, and transparent clinical recommendations systematically for treatment of allergic rhinitis on the basis of current best evidence.
  
  
  METHODS
  The authors updated ARIA clinical recommendations in collaboration with Global Allergy and Asthma European Network following the approach suggested by the Grading of Recommendations Assessment, Development and Evaluation working group.
  
  
  RESULTS
  This article presents recommendations about the prevention of allergic diseases, the use of oral and topical medications, allergen specific immunotherapy, and complementary treatments in patients with allergic rhinitis as well as patients with both allergic rhinitis and asthma. The guideline panel developed evidence profiles for each recommendation and considered health benefits and harms, burden, patient preferences, and resource use, when appropriate, to formulate recommendations for patients, clinicians, and other health care professionals.
  
  
  CONCLUSIONS
  These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children. Patients, clinicians, and policy makers are encouraged to use these recommendations in their daily practice and to support their decisions.
authors.affiliation: Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, Ontario, Canada.
authors.forename: Jan L
authors.initials: JL
authors.lastname: Brozek
authors.forename: Jean
authors.initials: J
authors.lastname: Bousquet
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Baena-Cagnani
authors.forename: Sergio
authors.initials: S
authors.lastname: Bonini
authors.forename: G Walter
authors.initials: GW
authors.lastname: Canonica
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Casale
authors.forename: Roy Gerth
authors.initials: RG
authors.lastname: van Wijk
authors.forename: Ken
authors.initials: K
authors.lastname: Ohta
authors.forename: Torsten
authors.initials: T
authors.lastname: Zuberbier
authors.forename: Holger J
authors.initials: HJ
authors.lastname: Schünemann
mesh_terms: D000328:Adult; D001249:Asthma / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic / Q000592:standards; D005260:Female; D017408:Guidelines as Topic / Q000592:standards*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011247:Pregnancy; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000517:prevention & control* / Q000628:therapy*; D014028:Tobacco Smoke Pollution / Q000009:adverse effects
chemical_list: D014028:Tobacco Smoke Pollution